文献速递肝病消化道肿瘤与早癌

eIF3f通过重塑脂肪酸生物合成促进肝细胞癌的肿瘤恶性程度

eIF3f promotes tumour malignancy by remodelling fatty acid biosynthesis in hepatocellular carcinoma.
PubMed 文献 · J Hepatol · 2025-03-26

本研究利用类器官模型、单细胞RNA测序和空间转录组学等技术,发现eIF3f在肝细胞癌中上调并与不良预后相关,其通过K48连接的去泛素化稳定ACSL4,促进脂肪酸生物合成和肿瘤恶性,进而减少CD8+ T细胞浸润;靶向eIF3f-ACSL4-脂肪酸生物合成轴可减缓肿瘤进展并增强抗PD-1疗效。

要点

  • eIF3f在肝细胞癌组织中上调,并与不良预后相关。
  • eIF3f通过K48连接的去泛素化稳定ACSL4,促进脂肪酸生物合成和肿瘤恶性。
  • 抑制eIF3f联合抗PD-1治疗在小鼠模型中显著提高抗肿瘤疗效。

核心结论

  • 靶向eIF3f-ACSL4-脂肪酸生物合成轴可减缓肝细胞癌进展并增强抗程序性细胞死亡蛋白1的疗效,提示eIF3f是肝细胞癌精准治疗的潜在靶点。

研究设计与样本

  • 研究采用类器官模型、单细胞RNA测序和空间转录组学鉴定肿瘤脂肪酸代谢关键基因,并利用代谢组学、蛋白质组学、代谢通量分析和透射电子显微镜评估代谢过程,通过多物种模型表征肿瘤恶性程度,使用飞行时间质谱流式细胞术和多重免疫组化分析免疫微环境变化,并通过脂质纳米颗粒实现靶向肝脏的基因敲低。

主要发现

  • 真核翻译起始因子3亚基f(eIF3f)在肝细胞癌组织中上调,并与不良预后相关。
  • eIF3f通过K48连接的去泛素化直接相互作用并稳定长链酰基辅酶A合成酶4(ACSL4),促进脂肪酸生物合成和肿瘤恶性。
  • 肿瘤微环境中脂肪酸水平升高间接减少CD8+ T细胞浸润。
  • 磷酸化的eIF3f增强eIF3f与ACSL4之间的相互作用。

临床怎么用

  • 作者认为eIF3f可作为肝细胞癌的新型治疗靶点,但需进一步临床研究确认靶向eIF3f在人患者中的疗效。

局限性

  • 需进一步临床研究确认靶向eIF3f在人患者中的疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Fatty acid metabolism is closely associated with hepatocellular carcinoma (HCC). Elucidating the molecules that influence fatty acid metabolism in HCC is important for developing precision therapies. However, uncovering the precise molecular mechanisms underlying changes in fatty acid metabolism in tumour cells is challenging. In this study, we aimed to determine the characteristics of fatty acid metabolism in HCC. METHODS: We employed organoid models, single-cell RNA sequencing, and spatial transcriptomics to identify key genes involved in tumour fatty acid metabolism. Metabolomics, proteomics, metabolic flux analysis, and transmission electron microscopy were utilized to evaluate this metabolic process. Tumour malignancy was characterized using multi-species models. Changes in the immune microenvironment were analysed by time-of-flight mass cytometry and multiplexed immunohistochemistry. Gene knockdown targeting the liver was achieved using lipid nanoparticles. RESULTS: Eukaryotic translation initiation factor 3 subunit f (eIF3f) is upregulated in HCC tissues and is associated with poor prognosis. eIF3f directly interacted with and stabilised long chain acyl CoA synthetase 4 (ACSL4) through K48-linked deubiquitination, promoting fatty acid biosynthesis and malignancy. The increased fatty acid levels in the tumour microenvironment indirectly reduced CD8+ T-cell infiltration. In addition, phosphorylated eIF3f enhanced the interaction between eIF3f and ACSL4. CONCLUSIONS: Targeting the eIF3f-ACSL4-fatty acid biosynthesis axis could decelerate the progression of HCC and enhance anti-programmed cell death-1 efficacy, implicating eIF3f as a potential target for precision therapy in HCC. IMPACT AND IMPLICATIONS: Fatty acid metabolism is closely associated with hepatocellular carcinoma (HCC), yet the underlying mechanisms involved remain unclear. Here, we found that eIF3f is upregulated in HCC and is associated with poor prognosis. eIF3f interacts with and stabilizes ACSL4, thereby promoting fatty acid biosynthesis. Additionally, increased fatty acid levels reduce CD8+ T-cell infiltration and activation. These findings are of significant importance for clinicians and researchers in the field of HCC treatment, as eIF3f inhibition combined with anti-PD-1 therapy significantly improved anti-tumour efficacy in a mouse model and could offer therapeutic benefits for patients. These findings have practical implications, as eIF3f could serve as a novel therapeutic target in HCC. However, further clinical studies are needed to confirm the efficacy of eIF3f targeting in human patients.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Zhou S, Zhang L, You Y, et al. eIF3f promotes tumour malignancy by remodelling fatty acid biosynthesis in hepatocellular carcinoma. J Hepatol. 2025. PMID: 40154622. doi:10.1016/j.jhep.2025.02.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。